FDA MedWatch - SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

If your email program has trouble displaying this email, view it as a web page
 
U.S. Food and Drug Administration Header

MedWatch - The FDA Safety Information and Adverse Event Reporting Program

A new MedWatch Safety Alert: SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area intended for: Patient, Endocrinology, Health Professional, Pharmacy was just added to the FDA MedWatch Webpage.
 
You can read the complete MedWatch Safety Alert that includes recommendations at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm618908.htm
 
 

U.S. Food and Drug Administration
10903 New Hampshire Avenue, Silver Spring, MD 20993
1-888-INFO-FDA (1-888-463-6332)
Privacy Policy | www.fda.gov
Manage Preferences or Unsubscribe from this List | Unsubscribe from all Email Lists

Comments

Popular Posts

Commissions Successfully

The State Department requires proof that you are the owner.

We have Your e-Wallet ready. Claim in 3hrs

Beneficiary countersignature modification

🙌 It was an exciting year

Reduced Payment!.

CHASE: Expired $2543,13 deposit check

You've Won $27,039.06 In Cash Prize.